Congress : ASCO
Authors : Laurence Albiges, Sylvie Negrier, Cécile Dalban, Gwenaelle Gravis, Christine Chevreau, Stephane Oudard, Brigitte Laguerre, Philippe Barthelemy, Delphine Borchiellini, Marine Gross-Goupil, Lionnel Geoffrois, Meryem Brihoum, Bernard Escudier, GETUG;
Experts group or program : GETUG
NIVOREN GETUG AFU 26 study, is a French multicenter prospective study to evaluate safety and efficacy of Nivolumab (N) in a broad “real world setting” in mRCC after failure of 1 or 2 tyrosine kinase inhibitors.
